MedTrace Logo

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT05976568 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 668

Last updated 2023-08-04

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of QL1706 in combination with bevacizumab and/or chemotherapy versus sintilimab in combination with bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.

Conditions

Interventions

DRUG

QL1706

7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Bevacizumab

15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Oxaliplatin injection

85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Capecitabine

1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle

DRUG

Sintilimab

200 mg administered as IV infusion on Day 1 of each 21-day cycle

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jia Fan · Fudan University

  • Shukui Qin · Nanjing Tianyinshan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2027-09-01
Completion
2027-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05976568 on ClinicalTrials.gov